- Report
- July 2023
- 115 Pages
Global
From €3674EUR$3,850USD£3,079GBP
- Report
- June 2023
- 103 Pages
Global
From €5679EUR$5,950USD£4,758GBP
- Report
- February 2023
- 244 Pages
Global
From €4008EUR$4,200USD£3,358GBP
- Report
- October 2022
- 200 Pages
Global
From €2291EUR$2,400USD£1,919GBP
- Report
- January 2024
- 200 Pages
Japan
From €5488EUR$5,750USD£4,598GBP
- Report
- August 2022
- 119 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- September 2022
- 159 Pages
Global
From €7158EUR$7,500USD£5,997GBP
- Report
- February 2024
- 117 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- April 2023
- 147 Pages
Global
From €4723EUR$4,949USD£3,957GBP
- Report
- November 2023
- 180 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- February 2024
- 125 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- August 2022
- 118 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- December 2022
- 112 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- May 2020
- 218 Pages
Global
From €14311EUR$14,995USD£11,991GBP
- Report
- November 2023
- 111 Pages
China
From €1718EUR$1,800USD£1,439GBP
- Drug Pipelines
- February 2019
- 300 Pages
Global
From €20996EUR$22,000USD£17,592GBP
- Report
- November 2023
- 105 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- April 2023
- 71 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- March 2025
- 50 Pages
Global
From €2529EUR$2,650USD£2,119GBP
- Report
- March 2025
- 50 Pages
Global
From €2529EUR$2,650USD£2,119GBP
Rivastigmine is a drug used to treat symptoms of Alzheimer's disease and other forms of dementia. It is a cholinesterase inhibitor, meaning it works by increasing the amount of a chemical messenger in the brain that helps nerve cells communicate with each other. It is used to treat mild to moderate dementia caused by Alzheimer's disease or Parkinson's disease. It is also used to treat mild to moderate dementia caused by Lewy body dementia. Rivastigmine is available in both capsule and patch form.
Rivastigmine is part of the Central Nervous System (CNS) drugs market, which includes drugs used to treat neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy. CNS drugs are used to treat a wide range of conditions, from mild to severe. The CNS drugs market is highly competitive, with many companies offering similar products.
Some companies in the Rivastigmine market include Novartis, Pfizer, Mylan, and Teva Pharmaceuticals. Show Less Read more
